Benitec Biopharma Files 8-K on Shareholder Votes
Ticker: BNTC · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing
Related Tickers: BNTC
TL;DR
BNTC filed an 8-K for shareholder votes - watch for corporate changes.
AI Summary
Benitec Biopharma Inc. filed an 8-K on December 2, 2025, reporting on matters submitted to a vote of security holders as of December 1, 2025. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 3940 Trust Way, Hayward, California.
Why It Matters
This filing indicates that Benitec Biopharma is engaging in corporate actions requiring shareholder approval, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding shareholder votes and does not immediately indicate significant financial or operational risks.
Key Numbers
- 001-39267 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-4620206 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Hayward, California (location) — Principal Executive Offices
- December 01, 2025 (date) — Date of earliest event reported
- December 2, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Benitec Biopharma's security holders?
The filing states that the report is pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and concerns 'Submission of Matters to a Vote of Security Holders,' but the specific details of the vote are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 01, 2025.
What is Benitec Biopharma Inc.'s principal executive office address?
The principal executive offices are located at 3940 Trust Way, Hayward, California, 94545.
Under which state was Benitec Biopharma Inc. incorporated?
Benitec Biopharma Inc. was incorporated in Delaware.
What is the SEC file number for Benitec Biopharma Inc.?
The SEC file number for Benitec Biopharma Inc. is 001-39267.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-12-02 17:27:38
Key Financial Figures
- $0.0001 B — ch registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indi
Filing Documents
- bntc-20251201.htm (8-K) — 65KB
- 0001193125-25-305475.txt ( ) — 165KB
- bntc-20251201.xsd (EX-101.SCH) — 23KB
- bntc-20251201_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On December 1, 2025, Benitec Biopharma Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting"). The 2025 Annual Meeting was held virtually. A total of 22,327,761 shares of the Company's common stock were present or represented by proxy at the 2025 Annual Meeting, representing 85.06% of the issued and outstanding shares entitled to vote at the meeting. The proposals voted upon and the final results of the vote were as follows: Proposal 1 – Election of Directors . The results were as follows: Nominee For Withheld Broker Non-Votes Dr. Jerel Banks 22,150,169 101,379 76,213 Megan Boston 21,693,741 557,807 76,213 Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm. The results were as follows: For Against Abstain 22,252,834 4,787 70,140 Proposal 3 – Advisory Vote on Executive Compensation. The results were as follows: For Against Abstain Broker Non-Votes 17,239,339 4,939,686 72,523 76,213 Each of the proposals received the required number of votes to be approved by the Company's stockholders.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. benitec biopharma inc. Date: December 2, 2025 By: /s/ Dr. Jerel A. Banks Name: Dr. Jerel A. Banks Title: Chief Executive Officer